Calcium Fracture Randomized Trial: What the Evidence Says

Quick Answer

Calcium Fracture Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The presence of calcium has important clinical implications, as it can hinder balloon expansion, limit stent delivery, and ultimately result in incomplete stent expansion and apposition. [Colletti Giuseppe (2026); evidence level 3]
• In turn, this is associated with an increased risk of in-stent restenosis, stent thrombosis, and adverse clinical outcomes (-). [Colletti Giuseppe (2026); evidence level 3]
• Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026); evidence level 3]
• A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. [Ahmad Areeb (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For calcium fracture randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Colletti Giuseppe (2026). Calcium modifying dedicated balloons: a contemporary review. DOI: 10.3389/fcvm.2026.1700877. PMCID: PMC13106395. PMID: 42039358. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13106395/
• Ahmad Areeb (2026). Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. DOI: 10.2106/JBJS.RVW.26.00021. PMCID: PMC13048325. PMID: 41945663. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-Non Commercial-No Derivatives License.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13048325/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.